Expand JUNS Menu
JUNS MENU

JUNS Latest Press Releases

-- August 21, 2026 --

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering Globe Newswire 12:20 PM
PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner Globe Newswire 7:00 AM

-- August 5, 2026 --

Jupiter Neurosciences, Inc. Announces Reverse Stock Split Globe Newswire 8:00 AM

-- July 21, 2026 --

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million Globe Newswire 7:13 AM
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 Globe Newswire 7:00 AM

-- July 7, 2026 --

Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson Globe Newswire 8:58 AM

-- June 10, 2026 --

Presenting on Emerging Growth Conference 93 Day 2 on June 11; Register to live stream Globe Newswire 7:00 AM

-- June 9, 2026 --

Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream Globe Newswire 7:00 AM

-- May 27, 2026 --

Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease Globe Newswire 7:30 AM

-- May 26, 2026 --

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering ACCESS Newswire 12:00 PM

-- May 21, 2026 --

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering Globe Newswire 5:15 PM

-- May 20, 2026 --

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering Globe Newswire 2:38 PM
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million Globe Newswire 8:15 AM
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech Globe Newswire 7:38 AM
Market Data Delayed 15 Minutes